Advanced Metastatic Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Melanoma is the third most prevalent form of cutaneous malignancy, following basal and squamous cell carcinoma. It stands as the leading cause of mortality among skin cancers. Differential diagnoses encompass Pigmented Basal Cell Carcinoma, Seborrheic Keratosis, various presentations of Squamous Cell Carcinoma (including Bowen’s disease, pagetoid, or pigmented types), Dermatofibroma, Other Cutaneous Metastases, and recurrent melanocytic nevi in Paget’s disease. The majority of melanoma diagnoses involve localized disease, typically treatable through surgical intervention. However, surgical methods are not curative for advanced melanoma (AM). Pembrolizumab, an anti-PD-1 molecule, is currently used for managing metastatic or unresectable melanoma, as well as for adjuvant therapy in patients with melanoma and lymph node involvement. The recommended dosage is 200 mg every three weeks (Q3W) or 400 mg every six weeks (Q6W). Nivolumab, another immunotherapy agent, is approved for treating metastatic or unresectable melanoma and as adjuvant therapy in patients with lymph node involvement. It obstructs programmed cell death 1 ligand 1 (PD-L1) from binding to PD-1, thus enhancing the immune system’s response to cancer cells. Ipilimumab, an anti-CTLA-4 antibody, inhibits CTLA-4 activity, enhancing T cell function and proliferation. Vemurafenib, a targeted therapy, is endorsed for managing metastatic or unresectable melanoma harboring the BRAF V600E mutation. The recommended dosage is four tablets of 240 mg every 12 hours.

Thelansis’s “Advanced Metastatic Melanoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Metastatic Melanoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Advanced Metastatic Melanoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Advanced Metastatic Melanoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Advanced Metastatic Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033